2nd liver transplant linked to good outcomes in PSC
A second liver transplant results in transplant and patient outcomes in people with primary sclerosing cholangitis (PSC) that are comparable or better than those…
Steve Bryson, PhD, Science Writer — 
Articles by Steve Bryson
Trial of HBV treatment candidate now enrolling final patient group
Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…
Maralixibat Phase 3 trial for cholestasis-related itch is enrolling
Enrollment is ongoing in a Phase 3 clinical trial that’s designed to evaluate Mirum Pharmaceuticals’ maralixibat for treatment-resistant itching, or pruritus, associated with rare…
Robotic-assisted Kasai liver surgery may help biliary atresia outcomes
A robotic-assisted Kasai surgical procedure results in less blood loss, faster bowel function recovery, and greater rates of clearing jaundice at three and six…
ABI-4334 shows promise in hepatitis B Phase 1b trial: Data
Oral therapy ABI-4334 shows potent antiviral activity in adults with chronic hepatitis B virus (HBV) infection, according to interim data from an ongoing Phase…
Distinct subtypes of MASLD discovered independently
An international team of researchers using different experimental approaches identified two distinct types of metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty…
Study: New ABCB4 mutations tied to different ages of PFIC3 onset
Two cases of progressive familial intrahepatic cholestasis type 3 (PFIC3) with markedly different ages of disease onset due to new mutations in the ABCB4…
New names given nonalcoholic fatty liver diseases fit children: Study
Almost every child and adolescent who met diagnostic criteria for forms of nonalcoholic fatty liver disease under their previous names — NAFL, NASH, or…
Maralixibat reduces itch in children with biliary atresia: Case series
Off-label treatment with Mirum Pharmaceuticals’ maralixibat led to clinically meaningful reductions in severe itching, or pruritus, in five children with biliary atresia, including…
FDA rejects full approval of Ocaliva as second-line PBC treatment
The U.S. Food and Drug Administration (FDA) has turned down a request by Intercept Pharmaceuticals for the full approval of Ocaliva (obeticholic acid) as…